Ann: DIRECTOR: PEB: Pacific Edge refreshes board of directors

• Release Date: 08/08/14 15:34
• Summary: DIRECTOR: PEB: Pacific Edge refreshes board of directors
• Price Sensitive: No
• Download Document  6.46KB

					PEB
08/08/2014 15:34
DIRECTOR

REL: 1534 HRS Pacific Edge Limited

DIRECTOR: PEB: Pacific Edge refreshes board of directors

Pacific Edge refreshes board of directors

Cancer diagnostic specialist, Pacific Edge, is looking to add further
commercial and international expertise to its Board as it builds its sales
and marketing platform in the United States and looks to expand its footprint
in other markets.

The Pacific Edge Board has been progressing a review of the skills and
capabilities required to provide the most appropriate governance as the
Company builds on its commercial platform.

Over the last 12 months, Bryan Williams, who recently held the position of
chairman of a NASDAQ listed therapeutic development company, has been
appointed as an independent Director to the Pacific Edge Board. In addition,
Bruce Nogales, who has significant skills and capabilities in medical
technology commercialisation in the US, joined the board of the Company's US
subsidiary, Pacific Edge Diagnostics USA Limited in 2013.

A further step in the Board refresh process has been triggered following the
recent resignation of Colin Dawson who has helped guide the Company through
its formative and early stages of growth. Colin's resignation will take
effect at the close of the annual shareholders meeting to be held in Dunedin
on 21 August 2014.

Chairman Chris Swann, said: "On behalf of the Board, I would like to thank
Colin for the significant contribution he has made in bringing the Company to
the point where it is today with its first cancer diagnostic system,
Cxbladder, acclaimed by clinicians in the United States and other markets as
leading technology in the accurate diagnosis of bladder cancer.

"Pacific Edge is now successfully commercialising the Cxbladder technology in
the world's largest health market, the US, and looking to further
developments of the Cxbladder system. In line with this, the Board has
identified a number of commercialisation skills and capabilities that would
be of value to the Company. We are in discussions with several candidates and
we hope to make an announcement on appointment of new directors in the near
future."

At the annual meeting shareholders will be invited to re-elect Chris Swann
and David Band as Directors. Shareholders will also be asked to support the
election of Chief Executive Officer David Darling as an Executive Director.

Future appointments are likely to increase the size of the Board from six to
eight members. The Company is seeking shareholder approval at the annual
meeting to increase the maximum pool of fees for non-executive directors by
$26,000 to $198,000.

The annual meeting is scheduled to begin at 4pm on 21 August 2014 and will be
held at the Dunedin Public Art Gallery.

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer.
Products in development and in clinical trials are accurate and simple to use
genomic and proteomic tools for the earlier detection, improved
characterisation and better management of gastric, bladder, colorectal
cancers and melanoma. The company has completed and released its first
product for the detection of bladder cancer, Cxbladder, and is actively
marketing the product to physicians and clinicians in New Zealand, Australia
and the USA and soon in Spain.
www.pacificedge.co.nz

ABOUT PACIFIC EDGE DIAGNOSTICS
Pacific Edge takes its exciting cancer detection tests to market through its
wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge
Diagnostics USA Ltd, and selected commercial partners in Australia and Spain,
Healthscope and Oryzon respectively.
www.pacificedgedx.com

ABOUT Cxbladder
Cxbladder is a proprietary, accurate molecular diagnostic test that enables
the non-invasive detection of bladder and other urinary tract cancers from a
small volume of urine. Cxbladder is commercialised in the USA as a Laboratory
Developed Test (LDT).  It provides physicians and clinicians with a quick,
cost effective and accurate measure of the presence of the cancer, and
provides urologists with the opportunity to reduce their reliance on the need
for invasive tests such as cystoscopy. The Cxbladder cancer detection test
has been validated by a multicentre, international clinical study.  Results
published in the Journal of Urology (Sept 2012) show that Cxbladder
out-performed all of the benchmark technologies in the clinical trial and
detected nearly all of the tumours of concern to a urologist; At a
performance of 82% sensitivity and 85% specificity the test sees 100% of T1,
100% of T2, 100% of T3, 100% of Tis and 100% of upper urinary tract cancers
as well as greater than 95% of high grade tumours.
www.cxbladder.com

ABOUT BLADDER CANCER
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist.

There are a number of 'at risk' occupations that have shown a much higher
incidence of bladder cancer. Fire fighters and fire control officers have
shown in a US study to have a twice the incidence of bladder cancer over non
fire fighters. Smoking is a significant contributing factor (over 50% in
males and 33% in females, and approximately one of every two new incidences
of bladder cancer is linked to smoking). Exposure to certain industrial
chemicals or carcinogens increases risks for some occupations e.g.
hairdressers, painters, printers, fire fighters and metal workers and
chemical engineers. Incidence increases with age so the older you are, the
greater the potential for bladder cancer.

Bladder cancer has a very high recurrence rate of approximately 50%-70% with
up to 30% of these recurring as later stage tumours. This is a higher
recurrence than for skin cancer! However, bladder cancers are highly
treatable, especially if detected in the early stages. If diagnosed early
there is a much higher probability of survival for early stage tumours
relative to later stage tumours. This makes timely and regular surveillance
and monitoring of this cancer a key element of the clinical process and of
the individual's annual healthcare plan.
End CA:00253648 For:PEB    Type:DIRECTOR   Time:2014-08-08 15:34:19